Essais liés9clinical trials
VilleNew Yorklocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT05673148

Ouvrir le site du centre

Essais cliniques associés

9
MoléculeIndication / populationPhaseNCTTitreStatut
Biospecimen Collection SEP Phase 3 NCT05457556 Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome ACTIVE_NOT_RECRUITING
Biospecimen Collection Cancer Phase 3 NCT07097142 Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study RECRUITING
Atezolizumab Cancer Phase 2 NCT03141684 Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma ACTIVE_NOT_RECRUITING
Biospecimen Collection Cancer Phase 3 NCT04269902 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study RECRUITING
Stereotactic Ablative Radiotherapy Cancer Phase 2 NCT05673148 Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial RECRUITING
Biopsy Procedure Cancer Phase 1/2 NCT05099003 A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) RECRUITING
Biospecimen Collection Cancer Phase 3 NCT05675410 A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab RECRUITING
Bone Scan Cancer Phase 2/3 NCT05691478 A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma SUSPENDED
Biospecimen Collection Lupus Phase 1 NCT03816345 Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO RECRUITING